Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marilena Fedele"'
Autor:
Fabio Efficace, Wael Al Essa, Uwe Platzbecker, Pasquale Niscola, Giuseppe A. Palumbo, Giovanni Caocci, Francesco Cottone, Massimo Breccia, Mario Luppi, Reinhard Stauder, Alessandra Ricco, Duska Petranovic, Frederic Baron, Maria Teresa Voso, Luana Fianchi, Chiara Frairia, Isabella Capodanno, Chiara Sarlo, Marilena Fedele, Roberto Massimo Lemoli, Rosangela Invernizzi, Daniele Vallisa, Nicola Di Renzo, Claudio Fozza, Maribel Doro, Johannes M. Giesinger, Marco Vignetti
Publikováno v:
HemaSphere, Vol 7, Iss 9, p e944 (2023)
Health-related quality of life (HRQoL) is an important goal of therapy for patients with myelodysplastic syndromes (MDS); however, little is known about HRQoL of these patients at clinical presentation. We report HRQoL profile of newly diagnosed pati
Externí odkaz:
https://doaj.org/article/e1521fb1a8594782b9707be424ba91a2
Autor:
Monica Carpenedo, Silvia Cantoni, Veronica Coccini, Marilena Fedele, Enrica Morra, Enrico Maria Pogliani
Publikováno v:
Hematology Reports, Vol 7, Iss 1 (2015)
Thrombopoietin mimetics are new treatment options for patients with immune thrombocytopenia (ITP). Because of their mechanism of action, long-term administration was envisioned in order to maintain effective thrombopoiesis. We report on 30 romiplosti
Externí odkaz:
https://doaj.org/article/e58f1e16be2b4a6bb716516ac04f5c8c
Autor:
Paola Perfetti, Elisabetta Terruzzi, Federica Cocito, Marilena Fedele, Mario Mauri, Luca Mologni, Andrea Aroldi, Matteo Parma, Rocco Piazza, Roberto Chiarle, Carlo Gambacorti-Passerini
Publikováno v:
Blood. 138:2276-2276
Introduction Mantle-cell lymphoma (MCL) is a B-cell non-Hodgkin Lymphoma (NHL) characterized by heterogenous behavior, ranging from indolent phenotype to highly aggressive and drug resistant one with dismal prognosis. Drug resistance may be generated
Autor:
Jo Caers, Manuela Canicattì, Antonio Cuneo, Rosangela Invernizzi, Claudio Fozza, Grazia Sanpaolo, Monica Crugnola, Duška Petranović, Marina Karakantza, Marilena Fedele, Andrea Patriarca, Nicola Di Renzo, Giovanni Caocci, Michael Lübbert, Valeria Santini, Charalampia Kyriakou, Huiyong Zhang, Fabio Efficace, Maria Teresa Voso, Uwe Platzbecker, Maribel Pelaez Dóro, Chiara Frairia, Luana Fianchi, Micaela Bergamaschi, Massimo Breccia, Mario Luppi, Isabella Capodanno, Reinhard Stauder, Francesco Cottone, Giuseppe A. Palumbo, Marco Vignetti, Chiara Sarlo, Daniele Vallisa, Alessandra Ricco, Pasquale Niscola
Publikováno v:
Blood. 132:2293-2293
Background: Understanding health-related quality of life (HRQOL) profile, including functional aspects and symptom burden, of yet untreated patients with myelodysplastic syndromes (MDS) is important to help clinicians to better identify subgroup of p
Autor:
Marilena Fedele, Veronica Coccini, Enrica Morra, Silvia Cantoni, Monica Carpenedo, Enrico Pogliani
Publikováno v:
Hematology Reports, Vol 7, Iss 1 (2015)
Hematology Reports
Hematology Reports
Thrombopoietin mimetics are new treatment options for patients with immune thrombocytopenia (ITP). Because of their mechanism of action, long-term administration was envisioned in order to maintain effective thrombopoiesis. We report on 30 romiplosti
Autor:
Franck Bonnetain, Mario Luppi, Huiyong Zhang, Rosangela Invernizzi, Amélie Anota, Marilena Fedele, Giuseppe A. Palumbo, Giovanni Caocci, Reinhard Stauder, Micaela Bergamaschi, Pasquale Niscola, Franco Mandelli, Luana Fianchi, Massimo Breccia, Anna Angela Di Tucci, Fabio Efficace, Marco Vignetti, Francesco Cottone, Uwe Platzbecker, Gianluca Gaidano
Publikováno v:
Blood. 128:1242-1242
BACKGROUND: Patients with higher risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS) have poor life expectancy making accurate prediction of overall survival (OS) a critical issue for optimal and perso
Autor:
Ilaria Dilda, Ivana Casaroli, Luisa Verga, Luca Guerra, Carlo Gambacorti-Passerini, Alessandra Perego, Lorenza Borin, Francesca Pavesi, Enrico Maria Pogliani, Giovanni Giudici, Marilena Fedele
Publikováno v:
Blood. 116:2877-2877
Abstract 2877 The Anaplastic Lymphoma Kinase (ALK) gene is fused to several partner genes (mainly NPM) in the majority of Anaplastic Large Cell lymphoma (ALCL) patients (pts). Deregulated ALK tyrosine kinase activity represents the driver alteration